PF-05280014 (TRASTUZUMAB BIOSIMILAR)
Early Breast Cancer
Pfizermonoclonal_antibodyPhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
891 Active assets in the Early Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lapatinib University of New Mexico | Phase 3 | BBB |
Darolutamide Vandana Abramson | Phase 2 | BBB |
Trastuzumab Duocarmazine Byondis B.V. | Phase 3 | BB |
Palbociclib Hoffmann-La Roche | Phase 4 | BB |
Loratadine Noha Mansour | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →